Timothy M. E. Davis

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Plasmodium knowlesi Malaria in Humans Is Widely Distributed and Potentially Life Threatening

Janet Cox‐Singh, Timothy M. E. Davis, K.-S. Lee et al. · Clinical Infectious Diseases · 2007 · 897 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Biology +14

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.

Gareth D. H. Turner, Helen Morrison, Marcus Jones et al. · PubMed · 1994 · 597 citations

Veterinary Medicine, Infectious Diseases, Pathology +17